Keyword: Achillion Pharmaceuticals
The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.
Enzyvant finds new CEO in former Alexion exec; Arix reappoints CEO after 5-month hunt; and MorphoSys CEO Moroney announces retirement.
Novartis brings in new CEO to clean up Korean branch; Achillion poaches CMO from uniQure; and Sensei hires a new CMO.
The appointment ends Zelenkofske’s brief time as chief medical officer of uniQure, the company he joined last summer from AstraZeneca.
Achillion appoints Joseph Truitt after CEO steps down; Lilly hires Leena Gandhi to lead new I-O team; and C4 promotes Andrew Phillips to CEO.
Joseph Truitt, who led Achillion’s business development for almost a decade, takes charge as the biotech nears midphase complement factor D data.
Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.
David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.
Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion.
J&J's Janssen and Achillion are looking to a 6-week regimen that could help boost the pharma giant's ailing position in hepatitis C.